Answers are grounded in this paper and cite their sources.
Daunorubicin, administered in large doses intermittently to 23 patients with acute nonlymphocytic leukemia (ANLL), produced a complete hematologic remission rate of 33%. Five of 16 (31%) previously untreated patients achieved complete hematologic remission. Clinical response was closely correlated with in vitro determinations of peripheral leukemic myeloblast daunorubicin reductase activity. The measurement of the activity of daunorubicin reductase in peripheral myeloblasts from patients with ANLL prior to therapy may serve to identify those patients least likely to respond favorably to daunorubicin therapy in the dose and schedule used in this study.
No takes yet. Share an insight, caveat, or question.
Greene et al. (1972) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: